Myeloproliferative disorders (MPDs) are a group of blood cancers traditionally treated using medications, blood filtration, and chemotherapy or radiation. In recent news, several studies and ...

PREVIOUS work 1 from this laboratory has demonstrated that certain patients with myeloproliferative disorders with hepatosplenomegaly have enhanced reticuloendothelial function as indicated by ...

Clinical trials offer a unique treatment experience when you live with myeloproliferative disorders. Lower cost of care, direct access to a specialized MDS medical team, and the opportunity to try ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

Gain-of-function mutations in JAK2 exon 12 and in the thrombopoietin receptor are observed in some patients with JAK2V617F-negative myeloproliferative disorders (MPD), suggesting constitutive ...

A Findlay man who was a successful businessman and very passionate about the community he loved and called home has passed ...

These remissions – minimal residual disease/operational cure – are sustained even after discontinuation of IFN-α2 for approximately 30 months (longest follow-up). IFN-α2 is efficacious and ...

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...

The Da Nang Hospital announced on March 31 that its department of neurology – musculoskeletal – clinical hematology has ...

Dr. Rachel Salit is a hematologist and oncologist, and member of the stem cell transplant faculty at Fred Hutch who focuses on improving stem cell transplant outcomes for patients who have ...